Drug Approval | July 08, 2022
Dr. Reddy's Laboratories updates on PAI of formulations facility
The company has been issued a Form 483 with two observations which the company will address within the stipulated timeline.
The company has been issued a Form 483 with two observations which the company will address within the stipulated timeline.
The ground floor of the formulation development laboratory is focused on solid orals, the first floor on injections, and the second floor houses the analytical lab
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
Veritaz has over 40 brands marketed across the acute and critical care therapeutic segments
Despite advances over the past 20 years, ovarian cancer treatment requires better standard of care
The pharma division’s domestic business generated turnover of Rs. 219.85 crore for the last financial year
Domestic business was up 41.9% YoY and 27.7% QoQ
The company expects a potential sales turnover of Rs.350-500 crores at 100 % capacity utilization
BALflu is approved by DCGI for emergency use for the treatment of COVID-19
Biocon Pharma will be responsible for drug development and manufacturing, while Libbs will leverage its deep expertise and reach in Brazil to import, distribute and market
Subscribe To Our Newsletter & Stay Updated
